Results of Operations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549  _______________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  _______________ Date of Report:  January 11, 2022 (Date of earliest event reported)  _______________ TENET HEALTHCARE CORP ORATION (Exact name of Registrant as specified in its charter)   Nevada   1-7293   95-2557091 (State of Incorporation)   (Commission File Number)   (IRS Employer Identification Number) 14201 Dallas Parkway Dallas , TX   75254 (Address of principal executive offices, including zip code) ( 469 ) 893-2200 (Registrant’s telephone number, including area code)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.05 par value THC NYSE 6.875% Senior Notes due 2031 THC31 NYSE Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging Growth Company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02. Results of Operations and Financial Condition. As previously announced, Tenet Healthcare Corporation (the “Company”) is presenting at the virtual J.P. Morgan Healthcare Conference on January 11, 2022, beginning at 3:00 p.m. Eastern time. A slide presentation of materials to be presented at the conference will be available on the investor relations section of the Company’s website at www.tenethealth.com/investors shortly ahead of the presentation. A live webcast of the Company’s presentation and question and answer session with senior management may also be accessed via that website. At the conference, the Company will disclose that although its financial statement close process is not yet fully completed, the Company anticipates its Adjusted EBITDA, excluding any fourth quarter stimulus grant income related to the pandemic, will meet or exceed the current Wall Street consensus estimate, as published by FactSet, of its Adjusted EBITDA for the year ended December 31, 2021 of approximately $3.301 billion. Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” - that is, statements that relate to future, not past, events. Forward-looking statements often contain words such as “expect,” “anticipate,” “assume,” “believe,” “budget,” “estimate,” “forecast,” “intend,” “plan,” “predict,” “project,” “seek,” “see,” “target,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include, but are not limited to, the factors disclosed under “Forward-Looking Statements” and “Risk Factors” in our Form 10-K for the year ended December 31, 2020, and subsequent Form 10-Q filings and other filings with the Securities and Exchange Commission. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TENET HEALTHCARE CORPORATION Date: January 11, 2022 By: /s/ T HOMAS A RNST Name: Thomas Arnst Title: Executive Vice President, Chief Administrative Officer and General Counsel